EmendoBio
Business Services · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
400 W 61st St, New York City, New York, ...Phone Number
(917) 675-5585Website
www.emendobio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About EmendoBio
EmendoBio is innovating traditional CRISPR solutions to enhance human health and address previously untreatable diseases. The company focuses on understanding genetic diseases to develop customized gene editing strategies that optimize nucleases and guide-RNAs for effective treatment. With a commitment to overcoming challenges, EmendoBio aims to unlock the full potential of CRISPR technology. Their services are tailored to meet the unique needs of each genetic disease, ensuring high editing activity while minimizing off-target effects.Explore more
EmendoBio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is EmendoBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when EmendoBio launches new products
Check out if EmendoBio is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if EmendoBio has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on EmendoBio recently announced quarterly report
Click to see if EmendoBio had a recent Job posting/layoffs
Funding: Get notified immidiatlly once EmendoBio has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
EmendoBio, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at EmendoBio
Recommended Actions
Reach out to Masked Content who joined EmendoBio as Masked Content
Find more new buyers
Compare Similar Companies to EmendoBio
Compare insights from companies similar to EmendoBio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
51-200
Private
$147.5M
2018
RR
Renuka RamanathanVice President Head of Corporate & Business Development
Company Profile Activity
Activity Insights
EmendoBio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
EmendoBio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about EmendoBio.
EmendoBio financials insights
Gather financial insights about EmendoBio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series B
$61M
EmendoBio Tech Stack
A closer look at the technologies used by EmendoBio
See more technologies
Most Recent Scoops
Project
, according to a front-line source in operations management, is in the midst of initiatives related to procurement software. The organization is currently evaluating various vendors.
Spending/Investment, Enterprise Software, Software, Logistics / Supply Chain, Operations, Sourcing / Procurement
Project
, according to a front-line source in operations management, is in the midst of initiatives related to communication systems. The organization is currently evaluating GitHub. EmendoBio will be decreasing funding to support these efforts.
Spending/Investment, Financial Planning, Funding, Software, Unified Communications, Strategic Communications, Communications, Finance, Operations
Project
, according to a front-line source in operations management, is in the midst of initiatives related to workforce management. The organization is currently evaluating various vendors. EmendoBio will be decreasing funding to support these efforts.
Spending/Investment, Financial Planning, Funding, Workforce Management, Finance, HR Operations, Operations
Project
, according to a front-line source in operations management, is planning to begin initiatives related to asset management software within six to nine months. The organization is currently evaluating SAP EAM.
Asset Management, Software, Operations
Project
Spending/Investment, Financial Planning, Funding, Digital Transformation, Finance, Operations
EmendoBio News & Media
Emendo Biotherapeutics’ next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting
NEW YORK--(BUSINESS WIRE)--Emendo Biotherapeutics presented the results of its next generation CRISPR-based gene editing approaches for several indications in an oral presentation and three posters at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) held May 16-19, 2022, in Washington, D.C. Emendo presented pre-clinical data for the treatment of ELANE-related Severe Congenital Neutropenia using an allele-specific editing approach, demonstrating the power of EmeEmendo Biotherapeutics and Seattle Children’s Research Institute Announce Collaboration to Develop CRISPR-based Therapeutic Strategy for Severe Congenital Neutropenia
NEW YORK & SEATTLE--(BUSINESS WIRE)--Collaboration formed to conduct preliminary research to inform protocol development ahead of gene editing clinical trialEmendo Biotherapeutics to Present New Data at 63rd ASH Annual Meeting & Exhibition
NEW YORK--(BUSINESS WIRE)--Emendo presenting data for allele-specific excision of mutant ELANE allele responsible for severe congenital neutropenia, using CRISPR.EmendoBio Gene Editing Company Acquired by AnGes, Inc.
NEW YORK & TEL AVIV, Israel & OSAKA, Japan--(BUSINESS WIRE)-- #BIOTECH--EmendoBio Inc., a leading next-generation CRISPR gene editing company, acquired by AnGes, Inc. for $250 million.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding EmendoBio
Sign Up For FreeTo access detailed company insights
EmendoBio is innovating traditional CRISPR solutions to enhance human health and address previously untreatable diseases. The company focuses on understanding genetic diseases to develop customized gene editing strategies that optimize nucleases and guide-RNAs for effective treatment. With a commitment to overcoming challenges, EmendoBio aims to un... Read More
